Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Cancer Cell

Volumn 24, Issue 6, 2013, Pages 777-790

  Chapuy, Bjoern ^a   McKeown, MichaelR ^a   Lin, CharlesY ^a   Monti, Stefano ^b   Roemer, MargarethaG M ^a   Qi, Jun ^a   Rahl, PeterB ^c   Sun, HeatherH ^d   Yeda, KellyT ^a   Doench, JohnG ^e   Reichert, Elaine ^a   Kung, AndrewL ^a   Rodig, ScottJ ^d   Young, RichardA ^c   Shipp, MargaretA ^a   Bradner, JamesE ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN BET; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENETICS; ENHANCER REGION; EPIGENETICS; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 84891953718     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.11.003     Document Type: Article

References (52)

1. Bartholomeeusen K., Xiang Y., Fujinaga K., Peterlin B.M. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J.Biol. Chem. 2012, 287:36609-36616.
2. Basso K., Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol. Rev. 2012, 247:172-183.
3. Bisgrove D.A., Mahmoudi T., Henklein P., Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl. Acad. Sci. USA 2007, 104:13690-13695.
4. Caro P., Kishan A.U., Norberg E., Stanley I.A., Chapuy B., Ficarro S.B., Polak K., Tondera D., Gounarides J., Yin H., et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 2012, 22:547-560.
5. Chen L., Monti S., Juszczynski P., Ouyang J., Chapuy B., Neuberg D., Doench J.G., Bogusz A.M., Habermann T.M., Dogan A., et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013, 23:826-838.
6. Cobaleda C., Schebesta A., Delogu A., Busslinger M. Pax5: the guardian of B cell identity and function. Nat. Immunol. 2007, 8:463-470.
7. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
8. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
9. Dey A., Chitsaz F., Abbasi A., Misteli T., Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA 2003, 100:8758-8763.
10. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
11. Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., Barsyte-Lovejoy D., Felletar I., Volkmer R., Müller S., Pawson T., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149:214-231.
12. Fuda N.J., Ardehali M.B., Lis J.T. Defining mechanisms that regulate RNA polymerase II transcription invivo. Nature 2009, 461:186-192.
13. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Trneny M., Bosly A., Ketterer N., Shpilberg O., Hagberg H., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J.Clin. Oncol. 2010, 28:4184-4190.
14. Greenwald R.J., Tumang J.R., Sinha A., Currier N., Cardiff R.D., Rothstein T.L., Faller D.V., Denis G.V. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2004, 103:1475-1484.
15. Greiner A., Müller K.B., Hess J., Pfeffer K., Müller-Hermelink H.K., Wirth T. Up-regulation of BOB.1/OBF.1 expression in normal germinal center B cells and germinal center-derived lymphomas. Am. J. Pathol. 2000, 156:501-507.
16. Hu S., Xu-Monette Z.Y., Tzankov A., Green T., Wu L., Balasubramanyam A., Liu W.M., Visco C., Li Y., Miranda R.N., et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013, 121:4021-4031. quiz 4250.
17. Johnson N.A., Slack G.W., Savage K.J., Connors J.M., Ben-Neriah S., Rogic S., Scott D.W., Tan K.L., Steidl C., Sehn L.H., et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J.Clin. Oncol. 2012, 30:3452-3459.
18. Kim U., Qin X.F., Gong S., Stevens S., Luo Y., Nussenzweig M., Roeder R.G. The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes. Nature 1996, 383:542-547.
19. Klein U., Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 2008, 8:22-33.
20. Lee T.I., Young R.A. Transcriptional regulation and its misregulation in disease. Cell 2013, 152:1237-1251.
21. Lenz G., Staudt L.M. Aggressive lymphomas. N.Engl. J. Med. 2010, 362:1417-1429.
22. Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B., Sougnez C., Cruz-Gordillo P., Knoechel B., Asmann Y.W., Slager S.L., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 2012, 109:3879-3884.
23. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
24. Luo Y., Roeder R.G. Cloning, functional characterization, and mechanism of action of the B-cell-specific transcriptional coactivator OCA-B. Mol. Cell. Biol. 1995, 15:4115-4124.
25. Marushige K. Activation of chromatin by acetylation of histone side chains. Proc. Natl. Acad. Sci. USA 1976, 73:3937-3941.
26. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 2011, 108:16669-16674.
27. Miyoshi, S., Ooike, S., Iwata, K., Hikawa, H., and Sugaraha, K. September 2009. Antitumor agent. International patent PCT/JP2008/073864 (WO/2009/084693).
28. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R.C., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
29. Monti S., Chapuy B., Takeyama K., Rodig S.J., Hao Y., Yeda K.T., Inguilizian H., Mermel C., Currie T., Dogan A., et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012, 22:359-372.
30. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
31. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
32. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., Chandwani R., Marazzi I., Wilson P., Coste H., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
33. Nutt S.L., Taubenheim N., Hasbold J., Corcoran L.M., Hodgkin P.D. The genetic network controlling plasma cell differentiation. Semin. Immunol. 2011, 23:341-349.
34. Ott C.J., Kopp N., Bird L., Paranal R.M., Qi J., Bowman T., Rodig S.J., Kung A.L., Bradner J.E., Weinstock D.M. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
35. Owen D.J., Ornaghi P., Yang J.C., Lowe N., Evans P.R., Ballario P., Neuhaus D., Filetici P., Travers A.A. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 2000, 19:6141-6149.
36. Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., Wells V.A., Grunn A., Messina M., Elliot O., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 2011, 43:830-837.
37. Peng J., Dong W., Chen L., Zou T., Qi Y., Liu Y. Brd2 is a TBP-associated protein and recruits TBP into E2F-1 transcriptional complex in response to serum stimulation. Mol. Cell. Biochem. 2007, 294:45-54.
38. Polo J.M., Juszczynski P., Monti S., Cerchietti L., Ye K., Greally J.M., Shipp M., Melnick A. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc. Natl. Acad. Sci. USA 2007, 104:3207-3212.
39. Puissant A., Frumm S.M., Alexe G., Bassil C.F., Qi J., Chanthery Y.H., Nekritz E.A., Zeid R., Gustafson W.C., Greninger P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3:308-323.
40. Ramachandrareddy H., Bouska A., Shen Y., Ji M., Rizzino A., Chan W.C., McKeithan T.W. BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells. Proc. Natl. Acad. Sci. USA 2010, 107:11930-11935.
41. Ren X., Siegel R., Kim U., Roeder R.G. Direct interactions of OCA-B and TFII-I regulate immunoglobulin heavy-chain gene transcription by facilitating enhancer-promoter communication. Mol. Cell 2011, 42:342-355.
42. Schreiber S.L., Bernstein B.E. Signaling network model of chromatin. Cell 2002, 111:771-778.
43. Sinha A., Faller D.V., Denis G.V. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem. J. 2005, 387:257-269.
44. Slack G.W., Gascoyne R.D. MYC and aggressive B-cell lymphomas. Adv. Anat. Pathol. 2011, 18:219-228.
45. Teitell M.A. OCA-B regulation of B-cell development and function. Trends Immunol. 2003, 24:546-553.
46. Wang H., Lee C.H., Qi C., Tailor P., Feng J., Abbasi S., Atsumi T., Morse H.C. IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood 2008, 112:4028-4038.
47. Yang Z., He N., Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 2008, 28:967-976.
48. Ye B.H., Cattoretti G., Shen Q., Zhang J., Hawe N., de Waard R., Leung C., Nouri-Shirazi M., Orazi A., Chaganti R.S., et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 1997, 16:161-170.
49. Zhang W., Prakash C., Sum C., Gong Y., Li Y., Kwok J.J., Thiessen N., Pettersson S., Jones S.J., Knapp S., et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ Tcells. J.Biol. Chem. 2012, 287:43137-43155.
50. Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA 2013, 110:1398-1403.
51. Zhao R., Nakamura T., Fu Y., Lazar Z., Spector D.L. Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation. Nat. Cell Biol. 2011, 13:1295-1304.
52. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.